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AntioxidantMitochondrial dysfunction has severe cellular consequences, and is linked to aging and neurological
disorders in humans. Impaired energy supply or Ca2+ buffering, increased ROS production, or control of
apoptosis by mitochondria may contribute to the progressive decline of long-lived postmitotic cells.
Mitochondrial biogenesis refers to the process via which cells increase their individual mitochondrial mass.
Mitochondrial biogenesis may represent an attempt by cells to increase their aerobic set point, or an attempt
to maintain a pre-existing aerobic set point in the face of declining mitochondrial function. Neuronal
mitochondrial biogenesis itself has been poorly studied, but investigations from other tissues and model
systems suggest a series of transcription factors, transcription co-activators, and signal transduction proteins
should function to regulate mitochondrial number and mass within neurons. We review data pertinent to
the mitochondrial biogenesis ﬁeld, and discuss implications for brain aging and neurodegenerative disease
research efforts.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Mitochondria are the only organelles in animal cells, besides the
nucleus, that contain their own separate DNA. The human mitochon-
drial DNA (mtDNA) is a 16,569 bp circular, double-stranded molecule
encoding 13 respiratory chain protein subunits, and 24 RNA compo-
nents (22 tRNAs and two rRNAs) necessary for mitochondrial protein
synthesis [1]. The majority of the ~1500 different mitochondrial pro-
teins are encoded by nuclear DNA (nDNA), translated in the cytoplasm
and transported into mitochondria [1]. The biogenesis of the respi-
ratory chain is therefore dependent on an intricate and still poorly
understood cross talk between mitochondrial and nuclear genomes.
Mammalian cells each have ~1000–10,000 copies of the mito-
chondrial genome. This high copy number of mtDNA ensures that
mutations affecting a single copy do not impact overall mitochondrial
function but does not prevent expansion of de novo mutations arising
in a single mtDNA molecule. Mitochondrial number and morphology
are controlled by an equilibriumofmitochondrial fusion andﬁssion [2]
that is vital for mitochondrial metabolism, energy production, Ca2+
signaling, reactive oxygen species (ROS) production, apoptosis, and
senescence [3–5]. Fusion allows the exchange of mitochondrial com-
ponents including mtDNA between different mitochondria. Severeof Medicine, Landon Center on
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ll rights reserved.damage of mitochondria impairs fusion resulting in fragmentation of
mitochondria that are then selectively removed by an autophagic
process called mitophagy [6]. Mitophagy prevents the release of pro-
apoptotic proteins from damaged mitochondria. Consistent with a
cytoprotective function of autophagy, apoptosis is suppressed upon
induction but induced upon inhibition of autophagy [7]. This
effectively maintains the integrity and homogeneity of the mitochon-
dria population throughout the cell [8–10]. This is vital for neuronal
homeostasis including synaptic function and imbalances in mitochon-
drial ﬁssion and fusion is implicated in neurodegenerative diseases
such as Charcot–Marie–Tooth neuropathy type 2A (CMT-2A) [11,12],
dominant optic atrophy [13,14], Parkinson's, Alzheimer's, and Hun-
tington's diseases [15–19].
The ﬁrst pathogenic mtDNA mutations in human patients were
reported in 1988 [20,21] with affected patients being either homo-
plasmic, i.e. having only mutated mtDNA [20], or heteroplasmic, i.e.
having a mixture of wild-type and mutated mtDNA [21]. Hetero-
plasmic mtDNAmutations segregate during cell division as there is no
mechanism to ensure that every mtDNA molecule is replicated once
and only once during each cell cycle [22]. A minimal threshold level of
a pathogenic mtDNA mutation is required to induce respiratory chain
dysfunction. This has been reported to range from 90% for some tRNA
mutations to 60% for mtDNA deletions [1], but research into threshold
phenomena have used to a large extent models that are insensitive to
aerobic perturbations and may thereby overestimate the amount of
mtDNA mutation needed to have a functional consequence.
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The brain is a highly metabolic tissue, and neurons in the central
nervous system have an intense demand for mitochondria [17].
Mitochondria provide most of the ATP for cellular reactions. ATP
production inmitochondria is coupled to an electron transport system
in which the passage of electrons down the various electron carriers is
associated with the transport of protons from the matrix into the
intermembrane space. The majority of these protons reenter the
mitochondrial matrix by the ATP synthase, thereby generating ATP.
However, approximately 20% ofmitochondrial oxygen consumption is
not coupled to ATP production, and protons enter the matrix through
the phospholipid bilayer and through uncoupling proteins, generating
heat [23].
Mitochondrial metabolism is also responsible for the majority of
the ROS production in cells [24]. The formation of ROS occurs when
unpaired electrons escape the electron transport chain and react with
molecular oxygen, generating superoxide. Superoxide can react with
DNA, proteins, and lipids; plays an important role in intracellular
signaling; and is associated with both neurodegenerative diseases and
aging [24]. ROS can also react with NO, generating reactive nitrogen
species (RNS) [25]. Themaintenance of physiologic ROS levels is critical
to normal cell functions, and thus prolonged increases in mitochondrial
activity can increase ROS levels and alter intracellular physiologic set
points.
Studies of aging brain mitochondria consistently report reductions
of complex I activity, complex IV activity, and increased ROS produc-
tion [26]. Other age-related mitochondrial changes include reduced
membrane potential and increased size. mtDNA mutations may con-
tribute to age-related mitochondrial decline. mtDNA deletions
accumulate with age in many tissues, especially brain [27]. It is easier
to ﬁnd low abundance, heteroplasmic point mutations (microheter-
oplasmy) in the brains of elderly individuals than in the brains of
young individuals [28,29]. The number of microheteroplasmic mtDNA
CO1 gene mutations inversely correlates with cytochrome oxidase
activity [29]. Mice with impaired mtDNA polymerase γ (mtPOLG)
proofreading show accelerated mutation accumulation, an age-
dependent progressive reduction of electron transport chain (ETC)
enzyme activities, and accelerated aging despite the fact that
oxidative stress markers are not increased [30–32].
Mitochondria are altered in brains of persons with certain neuro-
degenerative diseases [33,34]. There are activity reductions of com-
plex I in Parkinson's disease (PD), cytochrome oxidase in Alzheimer's
disease (AD), and multiple electron transport chain (ETC) enzymes in
Huntington's disease (HD). Mitochondrial dysfunction occurs in
amyotrophic lateral sclerosis and progressive supranuclear palsy.
Leber's hereditary optic neuropathy (LHON), a focal degeneration of
the optic nerves, arises from mutations in mtDNA-encoded complex I
genes and is associated with complex I dysfunction.
Falling oxidative phosphorylation capacity in aging human brain
associates with increased amounts of mtDNA [35,36]. This mtDNA
increase occurs in conjunction with a steady state decrease in mRNA
levels and presumably is compensatory. The status of mitochondrial
biogenesis in AD is unclear. In AD brain increasedmtDNA, ETC protein,
and ETC gene expression are reported [35,37]. Upregulated expression
of ETC genes occurs in mutant APP transgenic mice and low levels of
beta amyloid (Aβ) induce mitochondrial biogenesis [37,38]. Other
studies alternatively report reduced AD brain mtDNA and ETC gene
expression [39–42]. Perhaps neurons in different stages of disease
show different patterns of mitochondrial biogenesis.
Data pertinent to mitochondrial mass regulation in a neurode-
generative disease state are also inferred from transgenic mouse
models of HD. The R6/2 HDmouse shows reduction of the peroxisome
proliferator-activated receptor γ coactivator 1α (PGC1α), a transcrip-
tional coactivator critical to mitochondrial biogenesis [43]. Thissuggests polyglutamine-expanded huntingtin interference with mi-
tochondrial biogenesis. Beyond HD and AD, though, little is known
about mitochondrial biogenesis pathway activation or deactivation in
late-life neurodegenerative diseases but relevant precedents do exist.
For example, some mitochondrial encephalomyopathies such as the
myoclonic epilepsy and ragged red ﬁber (MERRF) syndrome, which
do exhibit neurodegeneration, show profound muscle cell mitochon-
drial proliferation [44].
3. Manipulation of mitochondrial biogenesis
A variety of interventions appear able to inﬂuence cell aerobic
setpoints in general and mitochondrial biogenesis speciﬁcally. Some
of these interventions are discussed below.
3.1. Caloric restriction
Caloric restriction (CR) induces endothelial NO synthetase (eNOS)
expressionwhich increases nitric oxide (NO) production and ultimately
mitochondrial biogenesis [45]. This process involves PGC1α [45,46].
This leads to increased autophagy, recycling damaged components and
producing newer, more efﬁcient organelles. This process is modulated,
in part, by mammalian target of rapamycin (mTOR) and forkhead box-
containing protein O (FOXO) transcriptional factors [47,48]. The arising
mitochondria have a reduced membrane potential, produce less ROS,
consume increased levels of oxygen and exhibit an improved ATP/ROS
ratio — leading to decreased energy expenditure [46].
3.2. Antioxidants
CR induces a switch to mitochondrial respiration and increased
ROS, which in turn, activates mitochondrial biogenesis. Subjecting
neurons to adverse stimuli in order to mitigate damage induced by
subsequent stressors has provided insight into the hormesis-mediat-
ing role of ROS [49]. ROS and reactive nitrogen species (RNS) may
mediate the protective inﬂuence of preconditioning on various cell
populations andmay actually operate as signal transduction elements.
The stress associated with the fasting state may inﬂict modest damage
upon metabolically active neuron mitochondria, which prompts the
neurons to increase mitochondrial mass and maintain mitochondrial
integrity via mechanisms that encompass mitophagy, mitochondrial
fusion, upregulated antioxidant defenses, and enhancedmtDNA repair
i.e. “mitohormesis” [50,51]. In this context ROS primarily appear to
serve as drivers of hormetic phenomena as opposed to drivers of cell
damage. It is nevertheless necessary to note mitochondria that are
damaged due to mutated mtDNA or to deleterious protein alterations
may not be able to withstand stressors tolerated by intact mitochon-
dria, and activate quality-control proteins such as the putative
mitochondrial membrane potential sensor, DAPK [52].
Recently the hormesis theory has been extended to the ROS-
generating effects of exercise [53,54]. ROS increase in skeletal muscle
during exercise and there is some evidence that such small, physio-
logical increases in ROS are required for normal increases in mito-
chondrial biogenesis following exercise [55]. Indeed, markers of
mitochondrial biogenesis do not increase during exercise-training if
rats are treatedwith vitamin C as a non-speciﬁc antioxidant [55]. PGC-
1α has been shown to switch on the antioxidant system when free
radicals begin to accumulate. This protective systemmay be what fails
in some neurodegenerative diseases. PGC-1α both drives the
mitochondria to make energy and establishes the maximum level of
free radicals the cell will accept as a consequence of increased aerobic
activity. As excess free radicals build up, the cell enters a state of
“oxidative stress,” which prompts the cell to produce more PGC-1α,
which in turn spurs the antioxidant defenses into action [56]. The
administration of antioxidants may actually serve to disrupt this
delicate and certainly physiologic feedback loop.
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The polyphenol resveratrol is a natural polyphenolic compound
mainly found in the skin of grapes and is well known for its phyto-
estrogenic and antioxidant properties [57]. It has been shown to
induce mitochondrial biogenesis by signiﬁcantly increasing SIRT1
activity through an allosteric interaction, resulting in the increase
of SIRT1 afﬁnity for both NAD+ and its acetylated substrates [58].
These ﬁndings are consistent with the fact that in various species,
resveratrol treatment mimics Sir2-dependent lifespan extension
during CR [58–60].
3.4. Exercise
Exercise is a powerful inducer ofmitochondrial biogenesis in skeletal
muscle [61,62]. It increases muscle AMP/ATP ratios and activates AMP-
activated protein kinase (AMPK), which proliferates mitochondria [63].
Drugs that activate AMPK also induce mitochondrial biogenesis.
3.5. Thiazolidinediones
Thiazolidinedione drugs activate peroxisome proliferator-activat-
ed receptorγ (PPARG) and are used to reduce insulin resistance in type
II diabetes [64–66]. These agents affect mitochondria and the con-
sequences of acute versus chronic exposure differ [67,68]. Thiazolidi-
nediones increase ETC uncoupling [69–72]. Although uncoupling
should reduce ROS, acute exposure of hepatocytes to a thiazolidine-
dione increases oxidative stress. Chronic exposure induces mitochon-
drial biogenesis in human subcutaneous adipose tissue, human
neuronal NT2 cells, andmouse brain [67,73,74]. The clinically available
thiazolidinediones, pioglitazone and rosiglitazone, poorly cross the
blood brain barrier but have been considered for treating AD [75–78].
Rationales are that thiazolidinedione anti-inﬂammatory effects or
insulin system modulation confers putative beneﬁts [78,79]. More
recently, it was proposed thiazolidinedione induced mitochondrial
effects are worth considering [80].
3.6. Pyruvate
Increasing concentrations of pyruvate have been shown to increase
mitochondrial biogenesis in myoblasts [81]. Acetyl-CoA generated
frompyruvate entering into themitochondria is converted into acetyl-
carnitine. Acetyl-carnitine in addition to liberatingmitochondrial CoA,
can pass out of the mitochondria and cell, providing an overﬂow
mechanism for excess energy supply when the cell is energy depleted.
Supplementing diets with acetyl-carnitine has been shown to help
maintain or improve mitochondrial function in rats [82,83]. Excess
pyruvate results in the production of lactate with the concomitant
oxidation of NADH to NAD+. The NAD+-dependent histone deacety-
lase SIRT1 interacts with PGC1α [84] and regulates PGC1α-dependent
gene expression in a nutrient-sensitive manner in hepatocytes [85].
4. Proteins and pathways implicated in mitochondrial biogenesis
4.1. PGC1α
While the mechanisms that underlie mitochondrial biogenesis vary
between tissues PGC1α often serves as a master regulator, modulating
~20% of the genes that are regulated during CR, including acute phase
response (APR) genes [86]. PGC1α co-activates numerousmetabolically
relevant nuclear andnon-nuclear receptor transcription factors [87–89].
It is highly expressed inbrownadipose tissue, skeletalmuscle, andbrain.
Nuclear respiratory factor 1 (NRF1) and nuclear respiratory factor 2
(NRF2) are PGC1α co-activated transcription factors. Their activation
coordinates expression of genes encoding mitochondrial proteins [90].
Part of this coordination includes expression of mitochondrial tran-scription factor A (TFAM), which increases levels and expression of
mtDNA [91,92]. In some tissues PGC1α increases expression of tran-
scription factors it subsequently co-activates, creating positive feedback
loops. For example, the estrogen-related factor α (ERRa) promoter
contains cis-elements that bind NRF2 and ERRa itself. PGC1α increases
NRF2 and ERRa expression, and subsequently co-activates them to
produce even more ERRa. ERRa then binds PGC1α to drive NRF1 ex-
pression [93,94]. PGC1α also co-activates antioxidant enzyme expres-
sion [95] and expression ofmammalianhomolog of tribble 3 (TRB-3), an
Akt pathway inhibitor [96].
PGC1α is inﬂuenced by post-translational modiﬁcation, including
acetylation (usually suppresses activity), p38 MAP kinase-mediated
phosphorylation (enhances activity by reducing binding of the
p160MBP repressor protein, as well as by increasing the PGC1α half-
life), and arginine methylation [89,97–100]. PGC1α levels are also
controlled by the cAMP response element binding protein (CREB) and
FOXO transcription factors. CREB activates the PGC1α promoter and
drives PGC1α expression [101,102]. In this function CREB acts in
conjunctionwith a family of calciumand cAMP-sensitive co-activators,
the transducer of regulated CREB binding protein family (NB: TORC;
not to be confused with mTORC). Of the three TORC proteins, under
basal conditions TORC1 and TORC2 are in the cytoplasm, and move to
the nucleus when calcium and cAMP levels rise. TORC1 is especially
prominent in the brain. Like CREB, forkhead in rhabdomyosarcoma
(FKHR; FoxO1) activates the PGC1α promoter by binding internally
located insulin response sequences [103]. It is activated by oxidative
stress, which favors nuclear over cytoplasmic localization, and by
SIRT1-mediated deacetylation [104,105]. Akt prevents FKHR tran-
scription, since phosphorylation causes cytoplasmic retention. Akt
phosphorylation of FoxO3 also prevents its nuclear localization.
FoxO3-mediated transcription is associated with longevity [106].
Somemitochondria-targeted, nuclear-encoded protein gene expres-
sion ismediated by signal protein 1 (Sp1) ormyocyte-enhancing factor-
2 (MEF2) rather than the NRFs. Other nuclear receptors not discussed
(PPARa, PPARG, thyroid hormone receptors, retinoid receptors, gluco-
corticoid receptors) contribute to mitochondrial biogenesis through
effects on PGC1α expression, PGC1α interactions, or both [107]. Along
with PGC1α two other related transcription factors, PGC-1-related
coactivator (PRC) and PGC-1-related estrogen receptor coactivator
(PERC), comprise the PGC-1 “family” of co-activators. There is functional
overlap within the family, although its members vary in promotional
emphasis. PRC may play a particularly important role in regulating
mitochondrial content in cultured ﬁbroblasts, which do not express
PGC1α [108].4.2. SIRT1
SIRT1 is activated by a risingNAD+/NADH ratio [99,109]. SIRT1 is a
member of the sirtuin family of NAD+-dependent class III histone
deacetylases (HDAC) [110–113]. SIRT1, deacetylates and thereby
activates the nuclear PGC1α, which in turn induces mitochondrial
biogenesis [114]. Although SIRT1 is largely nuclear where it deacety-
lates histones H3 and H4 aswell as transcription factors such as NF-κB,
p53, FOXO, Ku70, and PGC1α [115,116], it has however been shown to
shuttle between the nucleus and cytosol in response to oxidative
stress [115,117,118]. Since it requires NAD+ for its activation and as
substrate for deacetylase reactions, changes in the cellular NAD+/
NADH ratio, i.e., the redox state, inﬂuence its activity. Increased NAD+
biosynthesis and SIRT1 activation have been shown to protect axons
against degeneration [119]. However, sinceHDAC inhibitors, including
nicotinamide, confer neuroprotective effects in models of neurode-
generative diseases [120,121], the role of HDAC in neuronal survival
becomes complicated. Since both SIRT1 and PARP-1 utilize NAD+ for
their activity, depletion of cellular NAD+due to PARP-1 activationmay
inﬂuence SIRT1 activity [122,123]. SIRT1's requirement of NAD+ has
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4.3. AMPK
PGC1α function is also modulated by AMPK [124]. AMPK therefore
appears to be critical in the mitochondrial bioenergetic process, espe-
cially during exercise [125]. In muscle, PGC1α is activated by AMPK, a
heterotrimer affected by cell AMP/ATP ratios [126]. AMPK favors
catabolism, and serves as a counterweight to the anabolism-oriented
Akt pathway. Anabolic cell processes increase the AMP/ATP ratio,
prompting AMPK to increase cell catabolic processes. ADP phosphor-
ylation, glycolysis, mitochondrial biogenesis, and glucose uptake are
stimulated,while anabolic processes are concurrently inhibited. AMPK
is stimulated by events that reduce ATP production (hypoxia, glucose
deprivation, metabolic inhibitors) or that increase ATP consumption.
Rising cytoplasmic calcium levels typically increase ATP consumption
and activate AMPK. A calcium/calmodulin-dependent protein kinase
kinase (CaMKK) appears to mediate this, especially in neural tissue
[127,128]. Resveratrol activates AMPK in HepG2 cells and in C. elegans
liver [129,130]. In culturedmyocytes,ﬁbroblasts, andhepatocytes very
short duration (under 3h) thiazolidinedione exposure increased
AMP/ATP ratios and increased AMPK activity [131,132]. Chronic
thiazolidinedione administration also increased AMPK activity in rat
liver and adipose tissue [133,134]. Metformin, a diabetes drug, acti-
vates AMPK [135]. AMPK may also modulate the function of FOXO,
implying coordination of resistance to oxidative stress and energy
metabolism [136].
4.4. mTOR
mTOR regulates cell growth in response to nutrient status and
regulates PGC1α levels and oxidative phosphorylation capacity
[126,137]. It mediates both pro-survival and proliferative functions.
Its inhibitionwith rapamycin lowers mitochondrial membrane poten-
tial, oxygen consumption, and ATP synthetic capacity [138]. Its activity
is modulated by p53 and AMPK [139] and it impacts mitochondrial
function as part of a complex with PGC1α and the transcription factor
yin–yang 1 (YY1) [140]. ThemTORpathway can also self inhibit via the
s6 kinase [141]. Insulin may therefore promote mitochondrial
biogenesis as part of a general proliferative function, while stressors
promote it as a mechanism to ensure increased resistance to stress.
4.5. HIF1α/β
The HIF-1α/β (hypoxia induction factor 1α and β) transcription
factor heterodimer favors glycolysis over oxidative phosphorylation.
The HIF-1a component is degraded under normal oxygen concentra-
tions and accumulates under hypoxic conditions. HIF-1 suppresses
mitochondrial biogenesis [142]. This is at least partly mediated
through negative regulation of AMPK. Brief hypoxic exposure, on the
other hand, induces mitochondrial biogenesis through nitric oxide-
dependent physiology [143]. The fact that hypoxia is associated with
mitochondrial biogenesis while HIF-1, which is hypoxia-induced,
suppresses it is conceptually complex. Experimental details relating to
the cell type or hypoxia stimulus duration may inﬂuence outcomes.
5. TFAM and mitochondrial transcription factor B
Mitochondrial biogenesis induced by CR, resveratrol, exercise, or
pyruvate is regulated by crosstalk between nuclear and mitochondrial
genomes and is coordinated bynuclear co-activators such as PGC1α and
the nuclear respiratory factors (NRF-1 and NRF-2), which transactivate
genes for oxidative phosphorylation and protein importation [144–
146]. These transcription factors also mediate mtDNA transcription
and replication through two nuclear genes:mitochondrial transcriptionfactor A (TFAM) and its cofactor, mitochondrial transcription factor B
[144,145]. Activation of these molecular regulators of biogenesis
during adaptation to oxidative stress enhances cell and organ survival
[144,147,148].
6. Could mitochondrial biogenesis induction beneﬁt the brain?
The aging brain exhibits mitochondrial biogenesis although aging
muscle apparently does not [26,35,149,150]. Mitochondrial biogene-
sis may represent an attempt by cells to increase their aerobic set
point, or an attempt to maintain a pre-existing aerobic set point in the
face of decliningmitochondrial function. In the case of brain aging, it is
reasonable to consider that increased brain mitochondrial mass might
represent a compensatory response to longitudinal declines in brain
mitochondrial function. In AD, though, data suggest themitochondrial
biogenesis picture may be mixed. There are certainly fewer normal
mitochondria and more abnormal mitochondria in AD neurons.
Mitochondrial removal via lysosomes is increased [35]. Expression
of oxidative phosphorylation subunit genes also appears mixed, with
some studies showing decreased expression and others showing
increased expression (at least up through intermediate stages of the
disease) [35,41,151,152]. This raises the possibility that switching
from an enhanced state of mitochondrial biogenesis to a diminished
state of mitochondrial biogenesis could represent a key transition
between normal brain aging and AD. If so, then inducing mitochon-
drial biogenesis should represent a viable pharmacologic target for
the treatment of AD and other NDDs.
While enhancing mitochondrial biogenesis of abnormal brain
mitochondria might prove therapeutically useful for AD as well as
other neurodegenerative diseases associatedwith decreased oxidative
phosphorylation enzyme activities, safety issues require consider-
ation. For example, in onemouse study PGC1α cardiac overexpression
caused cardiomyopathy [153].
7. Mitochondrial therapeutics of neurodegenerative diseases
Since many neurodegenerative diseases cause mitochondria to
malfunction, it may be important to focus on developing methods to
repair and restore mitochondria. Already a few strategies are being
developed that open up ways for manipulating mitochondrial func-
tions and may allow for the selective protection or eradication of
neurons in the treatment of neurodegenerative diseases.
8. Recombinant-human mitochondrial transcription factor
A (rhTFAM)
A recent study shows that the humanmitochondrial genomecan be
manipulated from outside the cell to change expression and increase
mitochondrial energy production.Mitochondrial transcription factor A
(TFAM), a naturally occurring protein, can be engineered to rapidly
pass through cell membranes and target mitochondria. It has been
shown that rhTFAM acts on cultured cells carrying a mitochondrial
DNA disease aswell as labmice. rhTFAMenters and energizes the DNA
of the mice's mitochondria, enabling these mice to run two times
longer on their rotating rods than a control group cohort [154,155].
9. Dimebon
Dimebon (or Dimebolin hydrochloride) is an antihistamine drug
thatmay inhibit mitochondrial permeability transition pore and protect
neuronal mitochondria from mutant proteins such as amyloid beta
(Aβ), mutant Huntingtin and other mitochondrial toxic insults [156]. It
clinically reduced cognitive deﬁcits in AD patients in a phase II clinical
trial and may enhance cognition in healthy individuals [19,157].
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Because mitochondria are the primary producers of cell ROS,
oxidative damage of mitochondrial proteins or DNA is likely to con-
tribute to the mitochondrial dysfunction that is characteristic of many
neurodegenerative diseases [158]. Developing antioxidants that target
mitochondria such as MitoQ, MitoVitE, MitoPBN, MitoPeroxidase, SS-
tetra peptides, choline esters of glutathione and N-acetyl-L-cysteine
maybe useful in protecting neurons from excessive ROS. Initial studies
of aging and amyotrophic lateral sclerosis (ALS)-transgenic mice
found that these antioxidants enter themitochondria several hundred
folds compared to naturally occurring antioxidants, neutralize free
radicals rapidly and decrease mitochondrial toxicity. Therefore, such
mitochondrially targeted antioxidants might be promising candidates
to treat elderly persons and neurodegenerative disease patients [159].
11. Conclusions
In the brain, mitochondrial function declines with age and this
functional decline associates with increased mitochondrial biogenesis.
In various neurodegenerative disease states brain mitochondrial
function declines even further, perhaps to the point that mitochondrial
biogenesis can no longer compensate for functional declines. It is worth
considering that at some point neurons with impaired mitochondria
may reachapointwheremitochondrial biogenesis pathwaysdeactivate.
Neuron mitochondrial biogenesis has not been studied extensively,
although it is reasonable to expect that proteins and pathways impli-
cated in mitochondrial biogenesis in other tissues are also relevant in
neuron mitochondrial biogenesis. A complete and integrated picture of
mitochondrial biogenesis mechanisms is worth pursuing, as pharma-
cologic manipulations of brain mitochondrial biogenesis could prove
therapeutically useful.
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